Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 3
2014 2
2015 5
2016 3
2017 4
2018 3
2019 1
2020 2
2021 2
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Bahlis NJ, et al. Among authors: chu mp. Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783970 Free PMC article. Clinical Trial.
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, Su J, Jimenez-Zepeda VH, Song K, Louzada M, White D, Sebag M, Reiman A, Stakiw J, Kotb R, Bergstrom D, Aslam M, Kaedbey R, Venner CP, Gul E, Reece D. Côté J, et al. Among authors: chu mp. Blood Cancer J. 2023 Sep 5;13(1):137. doi: 10.1038/s41408-023-00905-8. Blood Cancer J. 2023. PMID: 37669949 Free PMC article.
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.
Ogiya D, Chyra Z, Verselis SJ, O'Keefe M, Cobb J, Abiatari I, Talluri S, Sithara AA, Hideshima T, Chu MP, Hájek R, Dorfman DM, Pilarski LM, Anderson KC, Adamia S. Ogiya D, et al. Among authors: chu mp. Blood Cancer J. 2023 Feb 3;13(1):23. doi: 10.1038/s41408-023-00791-0. Blood Cancer J. 2023. PMID: 36737429 Free PMC article.
The cure of ageing: vitamin D--magic or myth?
Chu MP, Alagiakrishnan K, Sadowski C. Chu MP, et al. Postgrad Med J. 2010 Oct;86(1020):608-16. doi: 10.1136/pgmj.2010.101121. Postgrad Med J. 2010. PMID: 20971712 Review.
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Katz DA, et al. Among authors: chu mp. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. doi: 10.1080/10428194.2022.2064981. Epub 2022 May 3. Leuk Lymphoma. 2022. PMID: 35503708 Free article. Clinical Trial.
28 results